Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy, such as lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well lomustine works in treating patients with stage III or stage IV non-small cell lung cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Collaborator: National Cancer Institute (NCI)
• Treatments: Lomustine

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed non-small cell bronchogenic carcinoma, including the following histologic subtypes:

• Squamous cell

• Adenocarcinoma

• Adenosquamous

• Large cell anaplastic

• Bronchoalveolar

• Non-small cell carcinoma not otherwise specified (NOS)

• Stage IIIB disease (with a pleural effusion) or stage IV disease

• Stage IV patients with brain metastases are eligible provided the brain metastases are clinically stable after treatment with surgery and/or radiation therapy

• Tumors must test positive for aberrant methylation of the MGMT gene by methylation-specific polymerase chain reaction

• Bidimensionally measurable or evaluable disease

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• No other active malignancies

• WBC ≥ 4,000/mm^3 OR absolute neutrophil count ≥ 2,000/mm^3

• Platelet count ≥ 100,000/mm^3

• Total bilirubin normal

• AST < 5 times upper limit of normal

• Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min

• No uncontrolled serious active infection

• Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• More than 3 weeks since prior chemotherapy

• No more than 2 prior chemotherapy regimens

• No prior therapy with nitrosoureas

• Recovered from prior radiation therapy